

SEQUENCE LISTING

<110> RIDDER, Ruediger
 MARTIN, Peter
 HERKERT, Matthias
 REICHERT, Anja
 TRUNK-GEHMACHER, Marcus

<120> COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF CANCERS

<130> 05033.0009.PCUS00

<150> PCT/EP2003/050318

<151> 07/17/03

<150> EP 02017069.2

<151> 07/29/02

<150> EP 02017058.5.2

<151> 07/29/02

<160> 23

<170> PatentIn version 3.3

<210> 1

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 1

Gly His Asp Asp Gly Gln Arg Pro Ser Gly Gly Ala Ala Ala Ala
 1 5 10 15

<210> 2

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 2

Val Val His Ile Pro Arg Leu Thr Gly Glu Trp Ala Ala Pro Gly
 1 5 10 15

<210> 3

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 3

Val His Ile Pro Arg Leu Thr Gly Glu Trp Ala Ala Pro Gly Ala
1 5 10 15

<210> 4

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 4

Arg Arg Pro Gly His Asp Asp Gly Gln Arg Pro Ser Gly Gly Ala
1 5 10 15

<210> 5

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 5

His Asp Asp Gly Gln Arg Pro Ser Gly
1 5

<210> 6

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 6

Ala Ala Glu Leu Gly Pro Gly Gly Gly
1 5

<210> 7

<211> 9

<212> PRT

<213> Artificial Sequence

<220>
 <223> HLA restricted peptide

 <400> 7

 Arg Arg Cys Pro Gly Gly Leu Pro Gly
 1 5

 <210> 8
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> HLA restricted peptide

 <400> 8

 Gly His Asp Asp Gly Gln Arg Pro Ser
 1 5

 <210> 9
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> HLA restricted peptide

 <400> 9

 Gly Gly Glu Asn Met Val Arg Arg Phe
 1 5

 <210> 10
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> HLA restricted peptide

 <400> 10

 Gln Leu Arg Arg Pro Arg His Ser His
 1 5

 <210> 11
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>

<223> HLA restricted peptide

<400> 11

Met Val Arg Arg Phe Leu Val Thr Leu
1 5

<210> 12

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 12

Val Leu Met Leu Leu Arg Ser Gln Arg
1 5

<210> 13

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 13

Arg Leu Gly Gln Gln Pro Leu Pro Arg
1 5

<210> 14

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 14

Arg Val Arg Val Phe Val Val His Ile
1 5

<210> 15

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 15

Thr Leu Arg Ile Arg Arg Ala Cys Gly
1 5

<210> 16

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 16

Arg Leu Thr Gly Glu Trp Ala Ala Pro
1 5

<210> 17

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 17

Met Val Arg Arg Phe Leu Val Thr Leu
1 5

<210> 18

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 18

Ala Ala Val Ala Leu Val Leu Met Leu
1 5

<210> 19

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 19

Ala Val Ala Leu Val Leu Met Leu Leu
1 5

<210> 20

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 20

Leu Met Leu Leu Arg Ser Gln Arg Leu
1 5

<210> 21

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 21

His Ile Met Gly Arg Gly Arg Cys Val
1 5

<210> 22

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 22

Ala Ala Pro Gly Ala Pro Ala Ala Val
1 5

<210> 23

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HLA restricted peptide

<400> 23

Gly Ala Pro Ala Ala Val Ala Leu Val
1 5

1